Common sensitizing mutations in epidermal growth factor receptor (cEGFR), including exon
19 deletions (19-Del) and exon 21 L858R substitution, are associated with high sensitivity to …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are recommended
first-line therapy for advanced non-small cell lung cancer (NSCLC) with sensitizing EGFR …

Introduction Epidermal growth factor receptor (EGFR) 19del and L858R mutation are known
as “common mutations” in non-small cell lung cancer (NSCLC) and predict sensitivities to …

Uncommon Epidermal Growth Factor Receptor (EGFR) mutations represent a distinct and
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …

Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …

Objectives Although the majority of epidermal growth factor receptor (EGFR)-mutant non-
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …

Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …

Introduction The genetic heterogeneity of non-small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) mutations may affect clinical responses and …

Exons 19–21 EGFR activating mutations are predictive biomarkers of response to EGFR
tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However …